GIKLY - Grifols Selagine team up to develop immunoglobulin eye drops

2023-03-06 09:07:53 ET

• Grifols ( NASDAQ: GRFS ) ( OTCPK:GIKLY ) said it entered a research, development and sublicense agreement with Selagine for developing and selling immunoglobulin eye drops for dry eye disease.
• Under the agreement, Selagine —  a spin-out company from the University of Illinois at Chicago (UIC) — will receive an upfront payment and annual collaboration fee.
• In addition, Spain-based Grifols committed to fund the development of immunoglobulin eye drops through FDA approval, which will be managed collaboratively by the two companies, including clinical, manufacturing and regulatory activities, the companies noted.
• Upon commercialization, Selagine will get royalties on net sales and milestone payments based on certain annual sales thresholds.
• Selagine will share a part of the royalties with UIC, according to the companies.
• The companies noted that an immunoglobulin eye drop is a biologic drug which contains naturally occurring functional antibodies from human plasma collected from healthy donors.

For further details see: